Price of BI’s diabetes drug Trajenta is cut 30% from July
By Lee, Tak-Sun | translator Kang, Shin-Kook
24.06.24 05:57:03
가나다라
0
Price adjusted per ex officio adjustment due to generic entry
Price of Jardiance Tab was reduced by 5% per PVA
Trajenta will receive an ex officio price cut due to the entry of its generic while Jardiance will see a price cut after completing price-volume agreement (PVA) negotiations.
According to industry sources on the 21st, the insurance ceiling price of Boehringer Ingelheim’s diabetes drug brands Trajenta and Jardiance will be adjusted as of July 1st.
Trajenta is a DPP-4 (dipeptidyl peptidase-4) inhibitor class, and Jardiance is an SGLT-2 (sodium-glucose co-transporter 2) inhibitor for diabetes.
Based on UBIST, Trajenta generated KRW 61.3 billion in
Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)